BSX vs. ABT, ISRG, SYK, MDT, BDX, EW, IDXX, RMD, DXCM, and STE
Should you be buying Boston Scientific stock or one of its competitors? The main competitors of Boston Scientific include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), and STERIS (STE). These companies are all part of the "health care equipment" industry.
Boston Scientific vs.
Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations.
Abbott Laboratories has higher revenue and earnings than Boston Scientific. Abbott Laboratories is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.5% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Abbott Laboratories had 42 more articles in the media than Boston Scientific. MarketBeat recorded 70 mentions for Abbott Laboratories and 28 mentions for Boston Scientific. Abbott Laboratories' average media sentiment score of 1.32 beat Boston Scientific's score of 0.91 indicating that Abbott Laboratories is being referred to more favorably in the media.
Abbott Laboratories presently has a consensus target price of $131.57, indicating a potential upside of 15.97%. Boston Scientific has a consensus target price of $97.26, indicating a potential downside of 1.49%. Given Abbott Laboratories' higher possible upside, equities analysts plainly believe Abbott Laboratories is more favorable than Boston Scientific.
Abbott Laboratories has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.
Boston Scientific received 109 more outperform votes than Abbott Laboratories when rated by MarketBeat users. However, 69.72% of users gave Abbott Laboratories an outperform vote while only 69.69% of users gave Boston Scientific an outperform vote.
Abbott Laboratories has a net margin of 13.99% compared to Boston Scientific's net margin of 11.26%. Abbott Laboratories' return on equity of 20.18% beat Boston Scientific's return on equity.
Summary
Abbott Laboratories beats Boston Scientific on 10 of the 19 factors compared between the two stocks.
Get Boston Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Boston Scientific Competitors List
Related Companies and Tools
This page (NYSE:BSX) was last updated on 1/20/2025 by MarketBeat.com Staff
